An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients

Inclusion Criteria: * Male or female, age ranging from 18 yrs to 70 yrs, with histologically or cytologically confirmed malignant disease * naive to chemotherapy or nonnaive with an interval of at least 14 days to the last one * Karnofsky index more than 70% and anticipated survival time more than 90 days * Scheduled to receive any of the following cytotoxic agents based combination chemotherapy (epirubicin 60 mg/m2, or cisplatin 75 mg/m2) on study Day 1 and the chemotherapy should be accomplished on study Day 1 * No emetic episodes and antiemetic medication during the 24 hours preceding chemotherapy administration * Adequate organ functions(No impairment to renal, hepatic, cardiac or bone marrow function ) * Use of reliable contraceptive measures (for females of childbearing potential) and negative pregnancy test at baseline visit * Provision of written informed consent Exclusion Criteria: * Inability to understand or cooperate with study procedures * Receipt of investigational drugs 30 days before study entry * Scheduled to receive any drug with antiemetic efficacy from 24 hrs before to 5 days after treatment * Contraindications to 5-HT3 receptor antagonists * Woman Patient with Pregnancy or lactation * Diagnosed with hypertension or severe infectious diseases * Obstructive symptom of gastrointestinal tract * Symptomatic brain metastasis or mental dysfunction * Baseline QTc \> 500 ms